BRIEF-Celator pharmaceuticals announces data for Vyxeos for newly diagnosed AML patients
April 18, 2016 at 09:11 AM EDT
* celator pharmaceuticals announces positive data for vyxeos in FLT3-ITD mutated acute myeloid leukemia (aml) cells derived from patients with newly diagnosed AML Source text for Eikon: Further company coverage:
